An examination of preventive effect of Carperitide for contrast induced nephropathy (CIN) in chronic kidney disease (CKD) patients

An examination of preventive effect of Carperitide for contrast induced nephropathy (CIN) in chronic kidney disease (CKD) patients - hANP for CIN in CKD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003892

Enrollment

100

Registered

2010-07-31

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD with coronary artery disease

Interventions

Carperitide group (intra-venous continuous injection of 0.025-0.05ug/kg/min 18-24h before and 6h after PCI or coronary angiography) Control group (intra-venous continuous injection of 5% glucose 18-24

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with renal insufficiency (eGFR(mL/min/1.73m2)<60) 2.Patients with coronary artery disease

Exclusion criteria

Exclusion criteria: 1.Patients with hemodialysis 2.cases with used contrast volume under 40ml, or over 300ml 3.Patients with previous adverse effect with Carperitide 4.female with pregnancy or possibility of pregnancy 5.Patients who judged that the medical attendant was inappropriate

Design outcomes

Primary

Measure	Time frame
1.acute and sub-acute renal injury after intervention or coronary angiography (chages of L-FABP, N-gal, Midkine, eGFR, urinary albumin, urinary creatinine and serum creatunine within 24h after contrast use) 2.renal injury at 48h and 7days after intervention or coronary angiography (changes of eGFR, urinary albumin, urinary creatinine, serum creatinine, L-FABP, N-gal, Midkine and cystatin C at 48h and 7days after contrast use)	—

Measure

Time frame

1.acute and sub-acute renal injury after intervention or coronary angiography (chages of L-FABP, N-gal, Midkine, eGFR, urinary albumin, urinary creatinine and serum creatunine within 24h after contrast use) 2.renal injury at 48h and 7days after intervention or coronary angiography (changes of eGFR, urinary albumin, urinary creatinine, serum creatinine, L-FABP, N-gal, Midkine and cystatin C at 48h and 7days after contrast use)

—

Secondary

Measure	Time frame
incidence of adverse effects of Carperitide	—

Countries

Japan

Contacts

Public ContactMutsuharu Hayashi

Nagoya university graduate school of medicine Departmrnt of CKD initiatives

muhayasi@med.nagoya-u.ac.jp052-744-5502

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026